Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 June 2025 | Story André Damons | Photo Department of Science, Technology, and Innovation
Prof Motlalepula Matsabisa
Prof Motlalepula Matsabisa, a specialist in indigenous knowledge systems from the Department of Pharmacology at the University of the Free State (UFS), and Jansie Niehaus, NSTF Executive Director and Company Director, at the Second Ministerial Belt and Road Science and Technology conference (BRT) in China.

Prof Motlalepula Matsabisa, a specialist in indigenous knowledge systems from the Department of Pharmacology at the University of the Free State (UFS), is part of a delegation with Prof Blade Nzimande, minister of Science, Technology, and Innovation (DSTI), to the Second Ministerial Belt and Road Science and Technology conference (BRT) in China. 

The conference is being held in Chengdu from 11-12 June 2025 and will gather representatives from state-level agencies, scientific academies, and innovation enterprises from countries involved in the Belt and Road Initiative, including members of the Association of Southeast Asian Nations (ASEAN) and the Shanghai Cooperation Organisation. The theme of the conference is “Together for Innovation, Development for All – Jointly Building a Scientific and Technological Innovation Community for the Belt and Road”. 

Prof Matsabisa, Research Director of the African Medicines Innovations and Technologies Development at the UFS, is the only person from a South African university to be invited by Prof Nzimande as part of this ministerial trip. Other members of the delegation include members from the minister’s department, CEOs and board members of agencies that report to the DSTI – namely Technology Innovation Agency (TIA), the National Science and Technology Forum (NSTF), Council for Scientific and Industrial Research (CSIR), National Advisory Council on Innovation, Human Sciences Research Council of South Africa, South African Council for Natural Scientific Professions, National Science and Technology Forum (NSTF), National Advisory Council on Innovation (NACI), South African National Space Agency and the National Research Foundation (NRF). 

As a guest professor at the Beijing University of Chinese Medicine (BUCM) in Beijing, Prof Matsabisa accompanied the delegation on a visit to the university where he has a longstanding relationship. The UFS has the only active university collaboration within the China-South African Science and Technology bilateral agreement.

 

Supporting around aspects of traditional medicine 

According to a statement on the South African government website, Prof Nzimande expressed the department’s intention to strengthen collaboration with the Beijing University and the Aerospace Research Institute of the Chinese Academy of Sciences, in the areas of indigenous knowledge systems and space science, respectively. The minister visited both the BUCM and the Aerospace Information Research Institute of the Chinese Academy of Sciences this week. 

“It is an honour to be part of the minister’s delegation given that I am the only person from a university amongst the agencies. The UFS is indeed very honoured to have been the only one identified to be in this ministerial trip. I am honoured to make connections with the decision-makers such as the chairperson of the board of TIA and the CEO of NSTF and all the other CEOs. It’s indeed an honour to share our work with people from NACI and the minister’s office at DSTI. This really could not have been a better opportune moment for me,” says Prof Matsabisa. 

According to him, he is there to support Prof Nzimande around aspects of traditional medicine as well as with his meeting with the Chinese Minister of Science and Technology during the signing of a letter of intent on traditional medicines including in the BRT conference where the minister will give a talk that will cover traditional medicines. Prof Matsabisa says he is looking forward to strengthening the relationships between the UFS and BUCM and China as well as sharing with the minister the joint projects and joint students from both institutions, hoping for continued support and funding.

“This trip has opened new opportunities. TIA has invited me and the UFS to be part of their new project on neurodegenerative diseases with Cuba. It was wonderful to hear that both the CEO and the chairperson of the board had already been briefed about me to be part of the project.

“It is also great to be present at the signing of the letter of intent on traditional medicine as it is important to know where the policies are heading.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept